Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration

Chest. 1994 May;105(5):1406-10. doi: 10.1378/chest.105.5.1406.


This retrospective chart review describes the efficacy and safety of long-term administration of intravenous alpha1-antitrypsin (AAT) in 14 patients with hereditary AAT deficiency and COPD. During the 12- to 48-month observation period, 12 to 14 patients had stabilization of functional status; 4 patients had reductions in hospitalizations. Thirteen of 14 patients had no decline in pulmonary function. Three patients had self-limited adverse reactions to the AAT with one patient requiring a brief hospitalization.

MeSH terms

  • Adult
  • Female
  • Forced Expiratory Volume
  • Humans
  • Infusions, Intravenous
  • Lung Diseases, Obstructive / complications*
  • Lung Diseases, Obstructive / physiopathology
  • Male
  • Middle Aged
  • Phenotype
  • Retrospective Studies
  • Vital Capacity
  • alpha 1-Antitrypsin / administration & dosage*
  • alpha 1-Antitrypsin / adverse effects
  • alpha 1-Antitrypsin Deficiency*


  • alpha 1-Antitrypsin